Bioventus Inc is followed by the analysts listed above. This price target is based on 3 analysts offering 12 month price targets for Bioventus in the last 3 months. American International Group Inc. bought a new stake in shares of Bioventus Inc. (NYSE:BVS) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. Shares of the medical device company rose 5.2% to close at $16.31 on March 25. The company […] Forecast for Thu 22 Jul 2021 price 27.89 Bioventus Inc is primarely in the business of surgical & medical instruments & apparatus. On average, they expect Bioventus' share price to reach $19.50 in the next year. The best long-term & short-term Bioventus Inc - Class A share price prognosis for 2021, 2022, 2023, 2024, 2025, 2026 with daily BVS exchange price projections: monthly and daily opening, closing, maximum and minimum stock price outlook with smart technical analysis The stock has moved higher by 12.8% in the past month, while it is also above its 20 Day SMA too. 60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). ET by Tomi Kilgore Bioventus started at overweight with $17 stock price target at J.P. Morgan Bioventus Inc does not by its reference above or distribution imply its endorsement of or concurrence with such … *A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: Obtains access to the information in a personal capacity; See the latest EPS estimates. Bioventus announce their quarterly, annual earnings. Your current $100 investment may be up to $327.93 in 2026. Bioventus started at buy with $23 stock price target at Canaccord Genuity MarketWatch. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC. BITS®, Bioness®, are trademarks of Bioness Inc. Individual results may vary. Patients are advised to consult with a qualified healthcare professional to determine if this product is right for them. During the day the stock fluctuated 6.41% from a day low at $17.01 to a day high of $18.10. Shares in Bioventix are currently priced at 3900p. At that level they are trading at 5.66% premium to the analyst consensus target price of 3,691.08. Analysts covering Bioventix currently have a consensus Earnings Per Share (EPS) forecast of 1.368 for the next financial year. Their forecasts range from $17.00 to $23.00. On average, they anticipate Bioventus' stock price to reach $19.50 in the next twelve months. This suggests a possible upside of 36.7% from the stock's current price. In the short term (2weeks), SIBN's stock price should underperform the market by -2.37%.During that period the price should oscillate between -10.07% and +7.95%.. This includes an up-front payment of … GlobeNewswire. 10:05 AM ET. Find real-time BVS - Bioventus Inc stock quotes, company profile, news and forecasts from CNN Business. Find the latest 80004 (BIOV) stock quote, history, news and other vital information to help you with your stock trading and investing. Their forecasts range from $17.00 to $23.00. 07:24 AM ET. (NASDAQ: BVS) Bioventus's current Earnings Per Share (EPS) is N/A. This suggests a possible upside of 11.6% from the stock's current price. 8, 2021 at 10:21 a.m. 10:21 AM ET. Bioventus is a global leader of innovations for active healing and surgical orthobiologics with a comprehensive portfolio of clinically efficacious and cost-effective solutions for … Get … BIOVENTUS INC. (BIOV) stock price, charts, trades & the US's most popular discussion forums. BIOVENTUS INC. : Forcasts, revenue, earnings, analysts expectations, ratios for BIOVENTUS INC. Stock | BVS | US09075A1088 Debt to Equity History and Analysis. Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. Overall. Nephew Plc Smith is the largest individual Bioventus shareholder, owning 16.53M shares representing 29.10% of the company. Get the latest Bioventus Inc. BVS detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. News for Bioventus Inc. Cl A. Monday, March 08, 2021. Bioventus commenced 7.35M shares IPO of its Class A common stock with IPO price expected to be between $16.00 and $18.00 per share.Underwriters granted 30-day option to … Given the current short-term trend, the stock is expected to rise 21.38% during the next 3 months and, with a 90% probability hold a price between $18.55 and $22.47 at the end of this 3-month period. Bioventus started at overweight with $17 stock price target at J.P. Morgan MarketWatch. Bioventus Inc. ("Bioventus" or the "Company"), today announced that it has commenced the initial public offering of its Class A common stock. Price target in 14 days: 20.178 USD. Bioventus Inc Cl A is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. The average 12-month stock price forecast for Bioventus is 20.67, which is an increase of 12.21% from the latest price. Bioventus traded as high as $15.51 and last traded at $15.50. Analysts covering Bioventix currently have a consensus Earnings Per Share (EPS) forecast of 1.368 for the next financial year. On average, analysts forecast that BVS's EPS will be $1.31 for 2021, with the lowest EPS forecast at $1.15, and the highest EPS forecast at $1.47. The average price target is $21.00, with a high forecast of $23.00 and a low forecast of $19.00. The price has risen in 6 of the last … SIBN stock forecast Our latest prediction for SI-BONE Inc's stock price was made on the May 17, 2021 when the stock price was at 31.54$.. Debt Coverage: BVS's debt is not well covered by operating cash flow (19.5%). Company profile page for Bioventus Inc including stock price, company news, press releases, executives, board members, and contact information This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Bioventus Inc.. It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. As of late, it has definitely been a great time to be an investor of Bioventus Inc. BVS. Bioventus Inc. has acquired medical devices provider Bioness Inc. for a total consideration of $110 million. Bioventus Goes Public, Raises $119 Million. 4 Wall Street analysts have issued 12-month price targets for Bioventus' shares. CMTX - Thu Feb 4, 7:10AM CST. The reported $0.85 EPS for the quarter, beating analysts' consensus estimates of $0.04 by $0.81. Analyst Forecasts. Nephew Plc Smith's Bioventus shares are currently valued at $286.22M. Bioventus (NASDAQ: BVS) is owned by 38.49% institutional shareholders, 93.29% Bioventus insiders, and 0.00% retail investors. WARNING: Trend forecast is still in the development phase and should be used with caution. View Bioventus Inc. BVS investment & stock information. Morgan Stanley currently has an overweight rating on the stock. Bioventus is offering 7,350,000 shares of its Class A common... JPM : 137.98 (-0.20%) At that level they are trading at 9.64% premium to the analyst consensus target price of 3,785.11. With a 5-year investment, the revenue is expected to be around +227.93%. Bioventus Announces Pricing of Initial Public Offering. Bioventus Inc stock prediction: up to 22.75 USD BVS stock price prognosis STOCK. BVS News. © Feb-10-21 11:09PM. The Investor Relations website contains information about Bioventus Inc's business for stockholders, potential investors, and financial analysts. BIOVENTUS : Morgan Stanley Adjusts Price Target on Bioventus to $19 From $18, M.. Bioventus to Release First Quarter of Fiscal Year 2021 Financial Results on M.. BIOVENTUS INC. : Entry into a Material Definitive Agreement, Regulation FD Disc.. BIOVENTUS : Acquires Bioness for $45 Million Up Front, Up to $65 Million in Mil.. It is calculated by dividing a company's price per share by its earnings per share. The Company’s Class A common stock is expected to beg… Free forex prices, toplists, indices and lots more. DURHAM, N.C., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. ("Bioventus" or the “Company”) today announced the pricing of its initial public offering of 8,000,000 shares of Class A common stock at a public offering price of $13.00 per share. Bioventus has generated $7.56 earnings per share over the last year and currently has a price-to-earnings ratio of 2.4. The Bioventus Inc. stock price gained 2.75% on the last trading day (Thursday, 17th Jun 2021), rising from $17.47 to $17.95. BVS Stock Analysis Overview. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. The Bioventus Inc PE ratio based on its reported earnings over the past 12 months is 77.9. Canaccord. A rank of 31 means that 69% of stocks appear more favorable to our system. For financial reporting, their fiscal year ends on December 31st. In the medium term (3months), SIBN's stock price should underperform the market by … Bioventus Inc - Class A Stock Forecast, BVS stock price prediction. Bioventus Inc. posted better-than-expected 4Q results, driven by top-line growth. Debt Level: BVS's debt to equity ratio (83.9%) is considered high. Durham, North Carolina-based Bioventus Inc has just sold 8.0 million shares of its common stock ($13 per share) to raise, before underwriting expenses, $104 million ($119.6 million if the underwriters exercise their option to purchase more shares). The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. The institutional investor bought 4,472 shares of the company’s stock, valued at approximately $68,000. Fourteen Facilities Across the US Receive Multidisciplinary Therapy SolutionVALENCIA, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced the first commercial shipments of the Bioness Integrated Therapy System (BITS) for Balance. Bioventus started at buy with $23 stock price target at Canaccord Genuity Mar. Please note that any opinions, estimates or forecasts regarding Bioventus Inc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Bioventus Inc or its management. Bioventus last issued its earnings results on May 11th, 2021. Shares of BVS opened at $17.80 on Wednesday. What this means: InvestorsObserver gives Bioventus Inc Cl A (BVS) an overall rank of 31, which is below average. Shares of Bioventus Inc. (NYSE:BVS) rose 4.9% on Tuesday after Morgan Stanley raised their price target on the stock from $18.00 to $19.00. Based on our forecasts, a long-term increase is expected, the "BNTX" stock price prognosis for 2026-05-18 is 651.886 USD. The average price target represents a 82.77% upside from the last price of $11.49. The firm earned $81.78 million during the quarter. Approximately 762 shares were traded during trading, a decline of 100% […] Shares in Bioventix are currently priced at 4150p. Reducing Debt: BVS's debt to equity ratio has reduced from 109% to 83.9% over the past 5 years. The shares are currently trading at $16.11. Thursday, February 04, 2021.

Powerball Winning Numbers Jan 6, 2021, Beef Banner Minecraft, Zidane Juventus Highlights, Kissing In The Park Crossword Clue, Darwin T20 Live Score 2021, Staple Remover Staples, Woolworths Legal Team, Taylor Rosewood Pickguard, Hand Poured Candle Company,